New Antibiotic Designed To Overcome MRSA Bacteria

A new topical antibiotic formulation, designed to overcome bacterial drug-resistance, is now available Over The Counter (OTC). Known as Tetracycline-ABC, it kills the most drug-resistant and deadly bacteria such as Staph, MRSA and Acinetobacter. End Quote

(1888PressRelease) November 09, 2010 - An innovative drug design to combat antibiotics-resistant bacteria was announced today by Phillips Company, a pharmaceutical manufacturer. The Tetracycline-ABC antibiotic is an improvement over older antibiotics in this class due to a carrier formulation that speeds the delivery of active ingredient deep into the cell structure of a wound. The unique formulation uses both physical and chemical mechanisms of action to kill bacteria. Most existing antibiotics use only a chemical mechanism for effectiveness, resulting in those drugs becoming less effective over time as bacteria evolve to become able to survive the effects of antibiotics.

This new physical approach uses an antibiotic formulation designed to enhance physical transport and physical cell penetration. The result is that the active ingredient is rapidly transported deep into a wound where the chemical mechanism of action can be more effective. The new antibiotic formulation is based on tetracycline, the world's most-used broad-spectrum antibiotic, according to Steve Keough, spokesman for Phillips Company.

In-vitro tests, in controlled laboratory conditions, have shown that the Zone of Inhibition or kill zone is significantly larger than the area where the product is applied. Keough further added, "Tetracycline-ABC topical antibiotic is clearly a best-in-class pharmaceutical solution, with applications across multiple fields of use." This new antibiotic formulation acts rapidly - usually within 24 to 36 hours - as compared to most other antibiotics that require several days of treatment for best results.

Methicillin Resistant Staphylococcus Aureus (MRSA), the most notorious antibiotic-resistant strain of staph bacteria, has been wreaking havoc throughout communities all over the world. According to the United States Centers for Disease Control, more people in the United States are dying of MRSA infections than because of AIDS; raising MRSA infection to epidemic proportions. To make matters even worse, some experts are now predicting an emergence of new strains of antibiotic-resistant bacteria in the future.

It is becoming more common for bacteria to develop drug resistance to a chemical kill mechanism. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their chemistry, but it takes numerous generations for bacteria to grow a new kind of cell wall structure.

"Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years," said Howard Phillips, the General Manager of Phillips Company. "This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug," according to Phillips.

The new drug formulation was carefully tested on ten of the most harmful kinds of bacteria and it was found to be the most effective against MRSA. The Tetracycline-ABC topical antibiotic kills all other harmful Gram positive and Gram negative bacteria that have been available for testing. Phillips Company believes this is the world's strongest broad-spectrum topical antibiotic. Tetracycline-ABC kills the most drug-resistant and the most deadly bacteria (Staph, MRSA and Acinetobacter), which cause community or hospital acquired infections.

Phillips Company is a pharmaceutical development company with manufacturing capacity of 50,000 units per month. Using the develop-and-license business model, the company licensed six pharmaceutical products in 2010. Tetracycline-ABC will likely be licensed to a larger company for manufacturing and commercialization in both OTC and prescription drug applications.

Check out http://www.PhillipsCompany.4T.com for more details and information.

###

Visit Phillips Company Website

space